These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29855066)

  • 1. Point estimation following two-stage adaptive threshold enrichment clinical trials.
    Kimani PK; Todd S; Renfro LA; Stallard N
    Stat Med; 2018 Sep; 37(22):3179-3196. PubMed ID: 29855066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point estimation in adaptive enrichment designs.
    Kunzmann K; Benner L; Kieser M
    Stat Med; 2017 Nov; 36(25):3935-3947. PubMed ID: 28783881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of estimation methods adjusting for selection bias in adaptive enrichment designs with time-to-event endpoints.
    Di Stefano F; Pannaux M; Correges A; Galtier S; Robert V; Saint-Hilary G
    Stat Med; 2022 May; 41(10):1767-1779. PubMed ID: 35098579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection.
    Kimani PK; Todd S; Renfro LA; Glimm E; Khan JN; Kairalla JA; Stallard N
    Stat Med; 2020 Aug; 39(19):2568-2586. PubMed ID: 32363603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation after subpopulation selection in adaptive seamless trials.
    Kimani PK; Todd S; Stallard N
    Stat Med; 2015 Aug; 34(18):2581-601. PubMed ID: 25903293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection.
    Carreras M; Brannath W
    Stat Med; 2013 May; 32(10):1677-90. PubMed ID: 22744936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial.
    Ji L; McShane LM; Krailo M; Sposto R
    Clin Trials; 2019 Dec; 16(6):599-609. PubMed ID: 31581815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.
    Lu QS; Chow SC; Tse SK
    J Biopharm Stat; 2019; 29(2):400-410. PubMed ID: 30599798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design considerations for two-stage enrichment clinical trials.
    Frieri R; Rosenberger WF; Flournoy N; Lin Z
    Biometrics; 2023 Sep; 79(3):2565-2576. PubMed ID: 36435977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study.
    Joshi A; Zhang J; Fang L
    Contemp Clin Trials; 2017 Dec; 63():19-29. PubMed ID: 28522422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enrichment design with patient population augmentation.
    Yang B; Zhou Y; Zhang L; Cui L
    Contemp Clin Trials; 2015 May; 42():60-7. PubMed ID: 25746817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data.
    Shimura M; Gosho M; Hirakawa A
    Stat Med; 2017 Jun; 36(13):2067-2080. PubMed ID: 28211076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point estimation following a two-stage group sequential trial.
    Grayling MJ; Wason JM
    Stat Methods Med Res; 2023 Feb; 32(2):287-304. PubMed ID: 36384365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point estimation for adaptive trial designs II: Practical considerations and guidance.
    Robertson DS; Choodari-Oskooei B; Dimairo M; Flight L; Pallmann P; Jaki T
    Stat Med; 2023 Jun; 42(14):2496-2520. PubMed ID: 37021359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A conditional error function approach for adaptive enrichment designs with continuous endpoints.
    Placzek M; Friede T
    Stat Med; 2019 Jul; 38(17):3105-3122. PubMed ID: 31066093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials.
    Bowden J; Glimm E
    Biom J; 2014 Mar; 56(2):332-49. PubMed ID: 24353149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program.
    Wang SJ
    J Formos Med Assoc; 2008 Dec; 107(12 Suppl):19-27. PubMed ID: 19129042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.
    Shimura M; Maruo K; Gosho M
    Pharm Stat; 2018 Sep; 17(5):400-413. PubMed ID: 29687592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.